Benjamin Y. Fong

Experts / Benjamin Y. Fong

Associate Teaching Professor

Benjamin Y. Fong is Honors Faculty Fellow at Barrett, the Honors College and Associate Director of the Center for Work & Democracy at Arizona State University.He is the author of Quick Fixes: Drugs in America from Prohibition to the 21st Century Binge (Verso 2023). He is also the co-editor (with Craig Calhoun) of The Green New Deal and the Future of Work (Columbia, 2022) and the author of Death and Mastery: Psychoanalytic Drive Theory and the Subject of Late Capitalism (Columbia, 2016). His writing can be found in Jacobin, Catalyst, The New York Times, Current Affairs, The Point, and other popular outlets, and it is collected at benfong.com.

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

By Benjamin Y. Fong

Clinical Articles

Pharmacology

Benjamin Y. Fong

Associate Teaching Professor

More from this expert

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Upcoming Healthed Webcast

Practical Strategies for Behaviour Management in Dementia

Tuesday 7th July, 7pm - 9pm AEST

Speaker

Dr Chrys Pulle

Geriatrician; Principal Investigator, Internal Medicine and Dementia Research Unit, The Prince Charles Hospital

Dr Chrys Pulle provides practical and evidence-based recommendations on how best these behavioural and psychological symptoms can be assessed and managed.

Benjamin Y. Fong

Associate Teaching Professor

More from this expert

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

FDA rejects MDMA-assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder.

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Sign up for a free Healthed account

Extra Details

PASSWORD RESET

Discover

Healthed

Upcoming Healthed Webcast

Practical Strategies for Behaviour Management in Dementia

Tuesday 7th July, 7pm - 9pm AEST

Speaker

Dr Chrys Pulle

Geriatrician; Principal Investigator, Internal Medicine and Dementia Research Unit, The Prince Charles Hospital

Dr Chrys Pulle provides practical and evidence-based recommendations on how best these behavioural and psychological symptoms can be assessed and managed.